Skip to main content
Premium Trial:

Request an Annual Quote

LumiraDx Secures FDA Emergency Use Authorization, UK Approval for COVID-19, Flu Test

NEW YORK – LumiraDx said Monday that it had nabbed US Food and Drug Administration Emergency Use Authorization and UK Health Security Agency Coronavirus Test Approvals process validation for LumiraDx's laboratory-based multiplex test for COVID-19 and influenza A and B.

The assay, dubbed LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete, uses the London-based firm's qSTAR single-step nucleic acid extraction and amplification methods on open RT-PCR instruments to detect and differentiate flu and SARS-CoV-2 infections within 20 minutes.

LumiraDx launched sales of the assay in June 2022 in the European Union and other markets that accept the CE-IVD marking. The recent regulatory decisions will allow commercialization in the US and UK.

Sanjay Malkani, president of LumiraDx's molecular diagnostics business, said in a statement that the high-throughput, highly sensitive test will give clinical diagnostic laboratories and reference laboratories fast and accurate results from a single sample.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.